Liver Fibrosis in Women with Chronic Hepatitis C: Evidence for the Negative Role of the Menopause and Steatosis and the Potential Benefit of Hormone Replacement Therapy

Overview

Journal Gut

Specialty Gastroenterology

Date 2006 Sep 29

PMID 17005762

Citations 41

Authors

Liana Codes

Tarik Asselah

Dominique Cazals-Hatem

Florence Tubach

Dominique Vidaud

Raymundo Parana

Pierre Bedossa

Dominique Valla

Patrick Marcellin

Affiliations

Soon will be listed here.

Abstract

Background And Aims: The rates of fibrosis progression in chronic hepatitis C are significantly different between males and females. The antifibrogenic effect of oestrogen has been proposed, possibly via inhibition of stellate cells. The aim of this study was to evaluate the severity of chronic hepatitis C in women, in relation to the menopause, steatosis and hormone replacement therapy (HRT).

Methods: From November 2003 to October 2004, women with chronic hepatitis C were enrolled prospectively. A questionnaire was completed prospectively and a blood sample was obtained on the day of biopsy. We identified characteristics associated with moderate/severe fibrosis using univariate and multivariate analysis.

Results: 251 women were included in the study. 122 women (52%) were menopausal and 65 were receiving HRT. 61 (24%) women with moderate/severe fibrosis (F2-F4, Metavir score) had a longer known duration of infection (>15 years), a higher body mass index and presented with steatosis more frequently than 190 (76%) women with mild fibrosis (F0-F1). Women with F2-F4 were more often menopausal (67% v 47%). The probability of fibrosis F2-F4 was lower for menopausal women receiving HRT (p = 0.012). Steatosis was more frequent and more severe in menopausal women.

Conclusions: Severity of fibrosis was associated with a longer duration of infection (>15 years), a higher body mass index, advanced steatosis and the menopause. Menopausal women receiving HRT presented with a lower stage fibrosis. These results reinforce the hypothesis of a protective role of oestrogens in the progression of fibrosis. Steatosis may be implicated in the progression of fibrosis after the menopause.

Citing Articles

Like a Rolling Stone? A Review on Spontaneous Clearance of Hepatitis C Virus Infection.

Rzymski P, Brzdek M, Dobrowolska K, Poniedzialek B, Murawska-Ochab A, Zarebska-Michaluk D Viruses. 2024; 16(9).

PMID: 39339862 PMC: 11435954. DOI: 10.3390/v16091386.

Prevalence of Non-Alcoholic Fatty Liver Disease and Its Impact on Fibrosis Risk in Inactive Chronic Hepatitis B Patients: Insights from a Cross-Sectional Study.

Al-Busafi S, Al Balushi A, Al Shuaili H, Mahmood D, Al Alawi A J Clin Med. 2024; 13(16).

PMID: 39200880 PMC: 11355821. DOI: 10.3390/jcm13164738.

Global burden of liver cirrhosis 1990-2019 and 20 years forecast: results from the global burden of disease study 2019.

Wang Y, Wang M, Liu C, Hao M, Wang W, Li Y Ann Med. 2024; 56(1):2328521.

PMID: 38727511 PMC: 11089929. DOI: 10.1080/07853890.2024.2328521.

Metabolic causes of liver disease among adults living with HIV from low- and middle-income countries: a cross-sectional study.

Plaisy M, Minga A, Wandeler G, Murenzi G, Samala N, Ross J J Int AIDS Soc. 2024; 27(4):e26238.

PMID: 38566493 PMC: 10988113. DOI: 10.1002/jia2.26238.

No gender differences in the 24-month course of non-invasive liver fibrosis markers after DAA therapy in HCV-mono and HCV/HIV-coinfected patients.

Collazos J, Perez-Is L, de la Fuente B, Morano L, Rivas-Carmenado M, Rodriguez M Sci Rep. 2024; 14(1):7534.

PMID: 38553507 PMC: 10980728. DOI: 10.1038/s41598-024-57845-x.

References

Asselah T, Rubbia-Brandt L, Marcellin P, Negro F . Steatosis in chronic hepatitis C: why does it really matter?. Gut. 2005; 55(1):123-30. PMC: 1856395. DOI: 10.1136/gut.2005.069757. View

Ramesh S, Sanyal A . Evaluation and management of non-alcoholic steatohepatitis. J Hepatol. 2005; 42 Suppl(1):S2-12. DOI: 10.1016/j.jhep.2004.11.022. View

Ferrari C, Urbani S, Penna A, Cavalli A, Valli A, Lamonaca V . Immunopathogenesis of hepatitis C virus infection. J Hepatol. 2000; 31 Suppl 1:31-8. DOI: 10.1016/s0168-8278(99)80371-7. View

Gervais A, Bacq Y, Bernuau J, Martinot M, Auperin A, Boyer N . Decrease in serum ALT and increase in serum HCV RNA during pregnancy in women with chronic hepatitis C. J Hepatol. 2000; 32(2):293-9. DOI: 10.1016/s0168-8278(00)80075-6. View

Adinolfi L, Gambardella M, Andreana A, Tripodi M, Utili R, Ruggiero G . Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001; 33(6):1358-64. DOI: 10.1053/jhep.2001.24432. View

Rigamonti C, Andorno S, Maduli E, Morelli S, Pittau S, Nicosia G . Iron, hepatic stellate cells and fibrosis in chronic hepatitis C. Eur J Clin Invest. 2002; 32 Suppl 1:28-35. DOI: 10.1046/j.1365-2362.2002.0320s1028.x. View

Xu J, Gong J, Chang X, Luo J, Dong L, Hao Z . Estrogen reduces CCL4- induced liver fibrosis in rats. World J Gastroenterol. 2002; 8(5):883-7. PMC: 4656580. DOI: 10.3748/wjg.v8.i5.883. View

Seeff L . Natural history of chronic hepatitis C. Hepatology. 2002; 36(5 Suppl 1):S35-46. DOI: 10.1053/jhep.2002.36806. View

Marcellin P, Asselah T, Boyer N . Fibrosis and disease progression in hepatitis C. Hepatology. 2002; 36(5 Suppl 1):S47-56. DOI: 10.1053/jhep.2002.36993. View

10.

. Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: recommendations and rationale. Ann Intern Med. 2002; 137(10):834-9. DOI: 10.7326/0003-4819-137-10-200211190-00013. View

11.

Poynard T, Mathurin P, Lai C, Guyader D, Poupon R, Tainturier M . A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003; 38(3):257-65. DOI: 10.1016/s0168-8278(02)00413-0. View

12.

Shimizu I . Impact of oestrogens on the progression of liver disease. Liver Int. 2003; 23(1):63-9. DOI: 10.1034/j.1600-0676.2003.00811.x. View

13.

Carr M . The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003; 88(6):2404-11. DOI: 10.1210/jc.2003-030242. View

14.

Asselah T, Boyer N, Guimont M, Cazals-Hatem D, Tubach F, Nahon K . Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut. 2003; 52(11):1638-43. PMC: 1773870. DOI: 10.1136/gut.52.11.1638. View

15.

Ryder S, Irving W, Jones D, Neal K, Underwood J . Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004; 53(3):451-5. PMC: 1773967. DOI: 10.1136/gut.2003.021691. View

16.

Strader D, Wright T, Thomas D, Seeff L . Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004; 39(4):1147-71. DOI: 10.1002/hep.20119. View

17.

Beinker N, Voigt M, Arendse M, Smit J, Stander I, KIRSCH R . Threshold effect of liver iron content on hepatic inflammation and fibrosis in hepatitis B and C. J Hepatol. 1996; 25(5):633-8. DOI: 10.1016/s0168-8278(96)80231-5. View

18.

Colle I, Hautekeete M . Remission of autoimmune hepatitis during pregnancy: a report of two cases. Liver. 1999; 19(1):55-7. DOI: 10.1111/j.1478-3231.1999.tb00010.x. View

19.

Yasuda M, Shimizu I, Shiba M, Ito S . Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology. 1999; 29(3):719-27. DOI: 10.1002/hep.510290307. View

20.

BISSELL D . Sex and hepatic fibrosis. Hepatology. 1999; 29(3):988-9. DOI: 10.1002/hep.510290351. View